AbbVie's dividend yield of 2.4% is solid, but more importantly, it's been growing at an impressive clip.
The stock isn't cheap, but it warrants consideration for a long-term portfolio.
If you're in the market for a healthcare stock for your long-term portfolio, pharmaceutical giant AbbVie (NYSE:ABBV) offers several compelling reasons to invest in.
Image source: Getty Images.
Missed AI’s "Act 1"? Act 2 Could Be 15x Bigger. Most investors think they missed the AI boat because they didn't buy Nvidia in 2005. But according to our analysts, we’re only at the end of "Act 1"—the R&D phase. "Act 2" is the global rollout. Continue »
Here's a closer look at AbbVie and some of those reasons to consider it. First, though, let's talk dividends.
AbbVie stock recently sported a dividend yield of 2.4%. That's quite solid, but it might have been higher had the stock not popped by 28% year to date (as of Nov. 18). (A stock's dividend yield is its total annual dividend amount divided by the stock price, so when the stock price rises, the yield falls, and vice versa.)
Better still, it's a growing dividend. The current $1.82 quarterly payout is up 5.2% from the previous $1.73, and up from $1.41 in 2022 and $0.57 in 2016. And AbbVie has hiked its payout for 53 years in a row, making it a Dividend King.
Let's say you're looking for $1,000 in annual income from AbbVie. How many shares would you need to own? The math is straightforward: The total payout for the year is $1.82 times four, or $7.28 for the year. Divide $1,000 by $7.28, and you'll get the needed number of shares: 137.36.
At a recent stock price of $284 per share, 137 shares will cost you... roughly $39,000.
But would you want to invest in AbbVie? I'm a shareholder myself, but I'd hesitate to jump in right now because the recent valuation seems a bit high. The recent price-to-sales ratio of 7.7, for example, is well above the five-year average of 5.4, and the forward-looking price-to-earnings (P/E) ratio of 17.6 is also well above the five-year average of 13.9.
So maybe just add it to your watch list, hoping for a lower entry point. Or just start a small position in it now -- as long as you aim to hang on for many years. Its last earnings report was good, with revenue up 10% year over year and immunology drugs Skyrizi and Rinvoq performing particularly well.
Before you buy stock in AbbVie, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AbbVie wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $315,271!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $896,981!*
Now, it’s worth noting Stock Advisor’s total average return is 768% — a market-crushing outperformance compared to 198% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of November 21, 2026.
Selena Maranjian has positions in AbbVie. The Motley Fool has positions in and recommends AbbVie. The Motley Fool has a disclosure policy.